Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
NCT05150691Phase 2Recruiting
- Sponsor
- Duality Biotherapeutics
- Start
- Jan 2022
- Primary completion
- Aug 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 6
01
Overview
A Phase 2 trial of trastuzumab pamirtecan in solid tumor, sponsored by Duality Biotherapeutics. Started Jan 2022; status: recruiting.
02
Drugs
trastuzumab pamirtecan
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05150691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05150691.